Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis

Barr, R. G.; Bourbeau, J.; Camargo, C. A.; Ram, F. S. F.
October 2006
Thorax;Oct2006, Vol. 61 Issue 10, p854
Academic Journal
Background: A systematic review was undertaken to evaluate the efficacy of tiotropium, a long acting anticholinergic drug, on clinical events, symptom scales, pulmonary function, and adverse events in stable chronic obstructive pulmonary disease (COPD). Methods: A systematic search was made of the Cochrane trials database, MEDLINE, EMBASE, CINAHL, and a hand search of 20 respiratory journals. Missing data were obtained from authors and the manufacturer. Randomised controlled trials of ⩾12 weeks' duration comparing tiotropium with placebo, ipratropium bromide, or long acting 32 agonists (LABA) were reviewed. Studies were pooled to yield odds ratios (OR) or weighted mean differences with 95% confidence intervals (CI). Results: Nine trials (8002 patients) met the inclusion criteria. Tiotropium reduced the odds of a COPD exacerbation (OR 0.73; 95% CI 0.66 to 0.81) and related hospitalisation (OR 0.68; 95% CI 0.54 to 0.84) but not pulmonary (OR 0.50; 95% CI 0.19 to 1.29) or all-cause (OR 0.96; 95% CI 0.63 to 1.47) mortality compared with placebo and ipratropium. Reductions in exacerbations and hospitalisations compared with LABA were not statistically significant. Similar patterns were evident for quality of life and symptom scales. Tiotropium yielded greater increases in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) from baseline to 6-12 months than did placebo, ipratropium, and LABA. Decline in FEV1 over 1 year was 30 ml (95% CI 7 to 53) slower with tiotropium than with placebo and ipratropium (data were not available for LABA). Reports of dry mouth and urinary tract infections were increased with tiotropium. Conclusions: Tiotropium reduced COPD exacerbations and related hospitalisations, improved quality of life and symptoms, and may have slowed the decline in FEV1. Long term trials are warranted to evaluate the effects of tiotropium on decline in FEV1 and to clarify its role compared with LABA.


Related Articles

  • 2008- review: Inhaled anticholinergics increase risk for major cardiovascular events in chronic obstructive pulmonary disease. Stanbrook, Matthew B. // ACP Journal Club;1/1/2009, Vol. 150 Issue 1, p4 

    The article presents author's comments on a study titled "Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis," by researcher S. Singh and colleagues. It states that Singh and...

  • Glycopyrrolate matches tiotropium in COPD.  // PharmacoEconomics & Outcomes News;7/7/2012, Issue 657, p10 

    The article discusses research on the quality of life of chronic pulmonary obstructive disease (COPD) patients taking glycopyrrolate compared with tiotropium, referencing a study by P. E. Korenblat and colleagues published in the May 23, 2012 issue of the "American Journal of Respiratory and...

  • Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Sutherland E R; Allmers H; Ayas N T; Venn A J; Martin R J; Sutherland, E R; Allmers, H; Ayas, N T; Venn, A J; Martin, R J // Thorax;Nov2003, Vol. 58 Issue 11, p937 

    Background: Chronic obstructive pulmonary disease (COPD) is a syndrome of chronic progressive airflow limitation which occurs as a result of chronic inflammation of the airways and lung parenchyma. However, the role of inhaled corticosteroids in the treatment of COPD is...

  • Patients with Asthma and Comorbid Allergic Rhinitis: Is Optimal Quality of Life Achievable in Real Life? Braido, Fulvio; Baiardini, Ilaria; Menoni, Stefania; Gani, Federica; Senna, Gian Enrico; Ridolo, Erminia; Schoepf, Veruska; Rogkakou, Anthi; Canonica, Giorgio Walter // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Objectives: Asthma trials suggest that patients reaching total disease control have an optimal Health Related Quality of Life (HRQoL). Moreover, rhinitis is present in almost 80% of asthmatics and impacts asthma control and patient HRQoL. We explored whether optimal HRQoL was reachable in a...

  • Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Aaron, S. D.; Fergusson, D.; Marks, G. B.; Suissa, S.; Vandemheen, K. L.; Doucette, S.; Maltais, F.; Bourbeau, J. F.; Goldstein, R. S.; Balter, M.; O’Donnell, D.; FitzGerald, M. // Thorax;Feb2008, Vol. 63 Issue 2, p122 

    Background: Clinical trials measure exacerbations of chronic obstructive pulmonary disease (COPD) inconsistently. A study was undertaken to determine if different methods for ascertaining and analysing COPD exacerbations lead to biased estimates of treatment effects. Methods: Information on the...

  • Review: anticholinergics in addition to β2 agonists improve outcome in children and adults with acute asthma. Rodrigo, G. J.; Castro-Rodriguez, J. A. // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p21 

    The article reports on a study which reviews various research to determine whether inhaled anticholinergic agents plus β2 agonists can enhanced outcome in children and adults with acute asthma exacerbations compared to β2 agonists alone. The studies examined used randomized controlled...

  • Commentary. Thien, Frank // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p21 

    The article comments on a study by G. J. Rodrigo and colleagues which reviews various research to determine whether inhaled anticholinergic agents plus β2 agonists can enhanced outcome in children and adults with acute asthma exacerbations compared to β2 agonists alone. The meta-analysis...

  • Moving forward.  // Pulse;2/25/2009 Early Treatment of COPD, Vol. 69, p6 

    The article offers information on the clinical trial results of the anticholinergic tiotropium (SPIRIVA®). It states that Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT®) trial recruited patients with chronic obstructive pulmonary disease to investigate the...

  • Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation. GROSS, NICHOLAS J. // Mayo Clinic Proceedings;Nov2008, Vol. 83 Issue 11, p1241 

    Chronic obstructive pulmonary disease is a prevalent condition associated with a high societal burden. Despite a decrease in the prevalence of smoking in the United States, the rates of morbidity and mortality associated with chronic obstructive pulmonary disease are expected to continue to...


Read the Article


Sign out of this library

Other Topics